Search

Your search keyword '"Sargent, Daniel J"' showing total 1,374 results
Start Over Author "Sargent, Daniel J"
1,374 results on '"Sargent, Daniel J"'

3. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

Author

Sjoquist, Katrin M, Renfro, Lindsay A, Simes, R John, Tebbutt, Niall C, Clarke, Stephen, Seymour, Matthew T, Adams, Richard, Maughan, Timothy S, Saltz, Leonard, Goldberg, Richard M, Schmoll, Hans-Joachim, Van Cutsem, Eric, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Tournigand, Christophe, Punt, Cornelis JA, Koopman, Miriam, Hurwitz, Herbert, Heinemann, Volker, Falcone, Alfredo, Porschen, Rainer, Fuchs, Charles, Diaz-Rubio, Eduardo, Aranda, Enrique, Bokemeyer, Carsten, Souglakos, Ioannis, Kabbinavar, Fairooz F, Chibaudel, Benoist, Meyers, Jeffrey P, Sargent, Daniel J, de Gramont, Aimery, and Zalcberg, John R

Subjects
Patient Safety, Colo-Rectal Cancer, Digestive Diseases, Prevention, Clinical Research, Cancer, Aged, Colorectal Neoplasms, Disease Progression, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Metastasis, Nomograms, Precision Medicine, Prognosis, Progression-Free Survival, Survival Analysis, Fondation Aide et Recherche en Cancerologie Digestive Group, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundEstimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for clinical trials. We constructed prognostic nomograms for one-year overall survival and six-month progression-free survival in metastatic colorectal carcinoma by using the ARCAD database.MethodsData from 22 674 patients in 26 randomized phase III clinical trials since 1997 were used to construct and validate Cox models, stratified by treatment arm within each study. Candidate variables included baseline age, sex, body mass index, performance status, colon vs rectal cancer, prior chemotherapy, number and location of metastatic sites, tumor mutation status (BRAF, KRAS), bilirubin, albumin, white blood cell count, hemoglobin, platelets, absolute neutrophil count, and derived neutrophil-to-lymphocyte ratio. Missing data (50% vs 50% vs

Published
2018

6. Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database

Author

Shi, Qian, de Gramont, Aimery, Grothey, Axel, Zalcberg, John, Chibaudel, Benoist, Schmoll, Hans-Joachim, Seymour, Matthew T, Adams, Richard, Saltz, Leonard, Goldberg, Richard M, Punt, Cornelis JA, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Porschen, Rainer, Tebbutt, Niall C, Fuchs, Charles, Souglakos, John, Falcone, Alfredo, Tournigand, Christophe, Kabbinavar, Fairooz F, Heinemann, Volker, Van Cutsem, Eric, Bokemeyer, Carsten, Buyse, Marc, and Sargent, Daniel J

Subjects
Clinical Trials and Supportive Activities, Digestive Diseases, Clinical Research, Cancer, Colo-Rectal Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antineoplastic Agents, Biomedical Research, Colorectal Neoplasms, Databases, Factual, Digestive System, Disease-Free Survival, ErbB Receptors, Humans, Middle Aged, Neoplasm Metastasis, Neoplasms, Outcome Assessment, Health Care, Prognosis, Protein Kinase Inhibitors, Randomized Controlled Trials as Topic, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeProgression-free survival (PFS) has previously been established as a surrogate for overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC treatment has advanced in the last decade with extended OS, this surrogacy requires re-examination.MethodsIndividual patient data from 16,762 patients were available from 22 first-line mCRC studies conducted from 1997 to 2006; 12 of those studies tested antiangiogenic and/or anti-epidermal growth factor receptor agents. The relationship between PFS (first event of progression or death) and OS was evaluated by using R(2) statistics (the closer the value is to 1, the stronger the correlation) from weighted least squares regression of trial-specific hazard ratios estimated by using Cox and Copula models.ResultsForty-four percent of patients received a regimen that included biologic agents. Median first-line PFS was 8.3 months, and median OS was 18.2 months. The correlation between PFS and OS was modest (R(2), 0.45 to 0.69). Analyses limited to trials that tested treatments with biologic agents, nonstrategy trials, or superiority trials did not improve surrogacy.ConclusionIn modern mCRC trials, in which survival after the first progression exceeds time to first progression, a positive but modest correlation was observed between OS and PFS at both the patient and trial levels. This finding demonstrates the substantial variability in OS introduced by the number of lines of therapy and types of effective subsequent treatments and the associated challenge to the use of OS as an end point to assess the benefit attributable to a single line of therapy. PFS remains an appropriate primary end point for first-line mCRC trials to detect the direct treatment effect of new agents.

Published
2015

8. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database

Author

Salem, Mohamed E., Yin, Jun, Weinberg, Benjamin A., Renfro, Lindsay A., Pederson, Levi D., Maughan, Timothy S., Adams, Richard A., Van Cutsem, Eric, Falcone, Alfredo, Tebbutt, Niall C., Seymour, Matthew T., Díaz-Rubio, Eduardo, Aranda, Enrique, Bokemeyer, Carsten, Heinemann, Volker, Wasan, Harpreet, de Gramont, Aimery, Grothey, Axel, Shi, Qian, Sargent, Daniel J., and Marshall, John L.

Published
2018
Full Text
View/download PDF

10. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Author

Pagès, Franck, Mlecnik, Bernhard, Marliot, Florence, Bindea, Gabriela, Ou, Fang-Shu, Bifulco, Carlo, Lugli, Alessandro, Zlobec, Inti, Rau, Tilman T, Berger, Martin D, Nagtegaal, Iris D, Vink-Börger, Elisa, Hartmann, Arndt, Geppert, Carol, Kolwelter, Julie, Merkel, Susanne, Grützmann, Robert, Van den Eynde, Marc, Jouret-Mourin, Anne, Kartheuser, Alex, Léonard, Daniel, Remue, Christophe, Wang, Julia Y, Bavi, Prashant, Roehrl, Michael H A, Ohashi, Pamela S, Nguyen, Linh T, Han, SeongJun, MacGregor, Heather L, Hafezi-Bakhtiari, Sara, Wouters, Bradly G, Masucci, Giuseppe V, Andersson, Emilia K, Zavadova, Eva, Vocka, Michal, Spacek, Jan, Petruzelka, Lubos, Konopasek, Bohuslav, Dundr, Pavel, Skalova, Helena, Nemejcova, Kristyna, Botti, Gerardo, Tatangelo, Fabiana, Delrio, Paolo, Ciliberto, Gennaro, Maio, Michele, Laghi, Luigi, Grizzi, Fabio, Fredriksen, Tessa, Buttard, Bénédicte, Angelova, Mihaela, Vasaturo, Angela, Maby, Pauline, Church, Sarah E, Angell, Helen K, Lafontaine, Lucie, Bruni, Daniela, El Sissy, Carine, Haicheur, Nacilla, Kirilovsky, Amos, Berger, Anne, Lagorce, Christine, Meyers, Jeffrey P, Paustian, Christopher, Feng, Zipei, Ballesteros-Merino, Carmen, Dijkstra, Jeroen, van de Water, Carlijn, van Lent-van Vliet, Shannon, Knijn, Nikki, Mușină, Ana-Maria, Scripcariu, Dragos-Viorel, Popivanova, Boryana, Xu, Mingli, Fujita, Tomonobu, Hazama, Shoichi, Suzuki, Nobuaki, Nagano, Hiroaki, Okuno, Kiyotaka, Torigoe, Toshihiko, Sato, Noriyuki, Furuhata, Tomohisa, Takemasa, Ichiro, Itoh, Kyogo, Patel, Prabhu S, Vora, Hemangini H, Shah, Birva, Patel, Jayendrakumar B, Rajvik, Kruti N, Pandya, Shashank J, Shukla, Shilin N, Wang, Yili, Zhang, Guanjun, Kawakami, Yutaka, Marincola, Francesco M, Ascierto, Paolo A, Sargent, Daniel J, Fox, Bernard A, and Galon, Jérôme

Published
2018
Full Text
View/download PDF

11. Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

Author

Sinicrope, Frank A, Mahoney, Michelle R, Smyrk, Thomas C, Thibodeau, Stephen N, Warren, Robert S, Bertagnolli, Monica M, Nelson, Garth D, Goldberg, Richard M, Sargent, Daniel J, and Alberts, Steven R

Subjects
Clinical Research, Genetics, Clinical Trials and Supportive Activities, Digestive Diseases, Colo-Rectal Cancer, Cancer, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Colonic Neoplasms, DNA Mismatch Repair, Female, Fluorouracil, Humans, Leucovorin, Male, Middle Aged, Neoplasm Staging, Organoplatinum Compounds, Prognosis, Proto-Oncogene Proteins, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins p21(ras), ras Proteins, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown.Patients and methodsResected, stage III colon carcinomas from patients (N = 2,686) randomly assigned to FOLFOX ± cetuximab (North Central Cancer Treatment Group N0147 trial) were analyzed for mismatch repair (MMR) protein expression and mutations in BRAF(V600E) (exon 15) and KRAS (codons 12 and 13). Association of biomarkers with disease-free survival (DFS) was determined using Cox models. A validation cohort (Cancer and Leukemia Group B 88903 trial) was used.ResultsdMMR was detected in 314 (12%) of 2,580 tumors, of which 49.3% and 10.6% had BRAF(V600E) or KRAS mutations, respectively. MMR status was not prognostic overall (adjusted hazard ratio [HR], 0.82; 95% CI, 0.64 to 1.07; P = .14), yet significant interactions were found between MMR and primary tumor site (P(interaction) = .009) and lymph node category (N1 v N2; P(interaction) = .014). Favorable DFS was observed for dMMR versus proficient MMR proximal tumors (HR, 0.71; 95% CI, 0.53 to 0.94; P = .018) but not dMMR distal tumors (HR, 1.71; 95% CI, 0.99 to 2.95; P = .056), adjusting for mutations and covariates. Any survival benefit of dMMR was lost in N2 tumors. Mutations in BRAF(V600E) (HR, 1.37; 95% CI, 1.08 to 1.70; P = .009) or KRAS (HR, 1.44; 95% CI, 1.21 to 1.70; P < .001) were independently associated with worse DFS. The observed MMR by tumor site interaction was validated in an independent cohort of stage III colon cancers (P(interaction) = .037).ConclusionThe prognostic impact of MMR depended on tumor site, and this interaction was validated in an independent cohort. Among dMMR cancers, proximal tumors had favorable outcome, whereas distal or N2 tumors had poor outcome. BRAF or KRAS mutations were independently associated with adverse outcome.

Published
2013

14. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology

Author

Sepulveda, Antonia R., Hamilton, Stanley R., Allegra, Carmen J., Grody, Wayne, Cushman-Vokoun, Allison M., Funkhouser, William K., Kopetz, Scott E., Lieu, Christopher, Lindor, Noralane M., Minsky, Bruce D., Monzon, Federico A., Sargent, Daniel J., Singh, Veena M., Willis, Joseph, Clark, Jennifer, Colasacco, Carol, Rumble, R. Bryan, Temple-Smolkin, Robyn, Ventura, Christina B., and Nowak, Jan A.

Published
2017
Full Text
View/download PDF

22. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Author

Franko, Jan, Shi, Qian, Meyers, Jeffrey P, Maughan, Timothy S, Adams, Richard A, Seymour, Matthew T, Saltz, Leonard, Punt, Cornelis J A, Koopman, Miriam, Tournigand, Christophe, Tebbutt, Niall C, Diaz-Rubio, Eduardo, Souglakos, John, Falcone, Alfredo, Chibaudel, Benoist, Heinemann, Volker, Moen, Joseph, De Gramont, Aimery, Sargent, Daniel J, and Grothey, Axel

Published
2016
Full Text
View/download PDF

25. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial

Author

Fleshman, James, Branda, Megan E., Sargent, Daniel J., Boller, Anne Marie, George, Virgilio V., Abbas, Maher A., Peters, Walter R., Jr, Maun, Dipen C., Chang, George J., Herline, Alan, Fichera, Alessandro, Mutch, Matthew G., Wexner, Steven D., Whiteford, Mark H., Marks, John, Birnbaum, Elisa, Margolin, David A., Larson, David W., Marcello, Peter W., Posner, Mitchell C., Read, Thomas E., Monson, John R. T., Wren, Sherry M., Pisters, Peter W. T., and Nelson, Heidi

Published
2019
Full Text
View/download PDF

28. CCR Translation for This Article from Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

Author

Schroen, Anneke T., primary, Petroni, Gina R., primary, Wang, Hongkun, primary, Thielen, Monika J., primary, Gray, Robert, primary, Benedetti, Jacqueline, primary, Wang, Xiaofei F., primary, Sargent, Daniel J., primary, Wickerham, Donald L., primary, Cronin, Walter, primary, Djulbegovic, Benjamin, primary, and Slingluff, Craig L., primary

Published
2023
Full Text
View/download PDF

30. Data from Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

Author

Schroen, Anneke T., primary, Petroni, Gina R., primary, Wang, Hongkun, primary, Thielen, Monika J., primary, Gray, Robert, primary, Benedetti, Jacqueline, primary, Wang, Xiaofei F., primary, Sargent, Daniel J., primary, Wickerham, Donald L., primary, Cronin, Walter, primary, Djulbegovic, Benjamin, primary, and Slingluff, Craig L., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legend from KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

Author

Yoon, Harry H., primary, Tougeron, David, primary, Shi, Qian, primary, Alberts, Steven R., primary, Mahoney, Michelle R., primary, Nelson, Garth D., primary, Nair, Suresh G., primary, Thibodeau, Stephen N., primary, Goldberg, Richard M., primary, Sargent, Daniel J., primary, and Sinicrope, Frank A., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 1 from KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

Author

Yoon, Harry H., primary, Tougeron, David, primary, Shi, Qian, primary, Alberts, Steven R., primary, Mahoney, Michelle R., primary, Nelson, Garth D., primary, Nair, Suresh G., primary, Thibodeau, Stephen N., primary, Goldberg, Richard M., primary, Sargent, Daniel J., primary, and Sinicrope, Frank A., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 1 from KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

Author

Yoon, Harry H., primary, Tougeron, David, primary, Shi, Qian, primary, Alberts, Steven R., primary, Mahoney, Michelle R., primary, Nelson, Garth D., primary, Nair, Suresh G., primary, Thibodeau, Stephen N., primary, Goldberg, Richard M., primary, Sargent, Daniel J., primary, and Sinicrope, Frank A., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Tables 1 - 2 from Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study

Author

Sargent, Daniel J., primary, Shi, Qian, primary, Gill, Sharlene, primary, Louvet, Christophe, primary, Everson, Richard B., primary, Kellner, Udo, primary, Clancy, Thomas E., primary, Pipas, J. Marc, primary, Resnick, Murray B., primary, Meyers, Michael O., primary, Wu, Tsung-Teh, primary, Huntsman, David, primary, Validire, Pierre, primary, Farooq, Umar, primary, Pavey, Emily S., primary, Beaudry, Guillaume, primary, Haince, Jean-Francois, primary, and Fradet, Yves, primary

Published
2023
Full Text
View/download PDF

40. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

Author

Tabernero, Josep, Lenz, Heinz-Josef, Siena, Salvatore, Sobrero, Alberto, Falcone, Alfredo, Ychou, Marc, Humblet, Yves, Bouché, Olivier, Mineur, Laurent, Barone, Carlo, Adenis, Antoine, Yoshino, Takayuki, Goldberg, Richard M, Sargent, Daniel J, Wagner, Andrea, Laurent, Dirk, Teufel, Michael, Jeffers, Michael, Grothey, Axel, and Van Cutsem, Eric

Published
2015
Full Text
View/download PDF

46. Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147

Author

Huang, Jocelin, Nair, Suresh G., Mahoney, Michelle R., Nelson, Garth D., Shields, Anthony F., Chan, Emily, Goldberg, Richard M., Gill, Sharlene, Kahlenberg, Morton S., Quesenberry, James T., Thibodeau, Stephen N., Smyrk, Thomas C., Grothey, Axel, Sinicrope, Frank A., Webb, Thomas A., Farr, Gist H., Jr., Pockaj, Barbara A., Berenberg, Jeffrey L., Mooney, Margaret, Sargent, Daniel J., and Alberts, Steven R.

Published
2014
Full Text
View/download PDF

49. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

Author

Zaanan, Aziz, Shi, Qian, Taieb, Julien, Alberts, Steven R., Meyers, Jeffrey P., Smyrk, Thomas C., Julie, Catherine, Zawadi, Ayman, Tabernero, Josep, Mini, Enrico, Goldberg, Richard M., Folprecht, Gunnar, Van Laethem, Jean Luc, Le Malicot, Karine, Sargent, Daniel J., Laurent-Puig, Pierre, and Sinicrope, Frank A.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results